- Title
- Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents
- Creator
- Chen, Qingjuan; Yang, Binhui; Liu, Xiaochen; Zhang, Xu D.; Zhang, Lirong; Liu, Tao
- Relation
- Theranostics Vol. 12, Issue 11, p. 4935-4948
- Publisher Link
- http://dx.doi.org/10.7150/thno.73223
- Publisher
- Ivyspring International Publisher
- Resource Type
- journal article
- Date
- 2022
- Description
- The histone acetyltransferases CBP and p300, often referred to as CBP/p300 due to their sequence homology and functional overlap and co-operation, are emerging as critical drivers of oncogenesis in the past several years. CBP/p300 induces histone H3 lysine 27 acetylation (H3K27ac) at target gene promoters, enhancers and super-enhancers, thereby activating gene transcription. While earlier studies indicate that CBP/p300 deletion/loss can promote tumorigenesis, CBP/p300 have more recently been shown to be over-expressed in cancer cells and drug-resistant cancer cells, activate oncogene transcription and induce cancer cell proliferation, survival, tumorigenesis, metastasis, immune evasion and drug-resistance. Small molecule CBP/p300 histone acetyltransferase inhibitors, bromodomain inhibitors, CBP/p300 and BET bromodomain dual inhibitors and p300 protein degraders have recently been discovered. The CBP/p300 inhibitors and degraders reduce H3K27ac, down-regulate oncogene transcription, induce cancer cell growth inhibition and cell death, activate immune response, overcome drug resistance and suppress tumor progression in vivo. In addition, CBP/p300 inhibitors enhance the anticancer efficacy of chemotherapy, radiotherapy and epigenetic anticancer agents, including BET bromodomain inhibitors; and the combination therapies exert substantial anticancer effects in mouse models of human cancers including drug-resistant cancers. Currently, two CBP/p300 inhibitors are under clinical evaluation in patients with advanced and drug-resistant solid tumors or hematological malignancies. In summary, CBP/p300 have recently been identified as critical tumorigenic drivers, and CBP/p300 inhibitors and protein degraders are emerging as promising novel anticancer agents for clinical translation.
- Subject
- CBP/p300; gene transcription; tumorigenesis; small molecule inhibitors; cancer therapy
- Identifier
- http://hdl.handle.net/1959.13/1488685
- Identifier
- uon:52505
- Identifier
- ISSN:1838-7640
- Language
- eng
- Reviewed
- Hits: 1092
- Visitors: 1085
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|